Tolvaptan Zentiva k.s. (Tolvaptan 7.5 mg)
Low-dose oral vasopressin V2-receptor antagonist for adults with hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Tolvaptan Zentiva k.s. is a prescription-only oral medicine containing 7.5 mg of tolvaptan, a selective vasopressin V2-receptor antagonist. It is indicated in adults for the treatment of hyponatraemia (abnormally low blood sodium) caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The 7.5 mg strength represents a deliberately gentle starting dose, particularly useful in elderly or frail patients, those with moderate hyponatraemia, or individuals at elevated risk of osmotic demyelination syndrome, where a slower and more predictable rise in serum sodium is clinically preferable. This guide covers indications, dosage, side effects, contraindications, drug interactions, liver function monitoring, and practical advice for patients taking Tolvaptan Zentiva k.s.
Quick Facts About Tolvaptan Zentiva k.s.
Key Takeaways About Tolvaptan Zentiva k.s.
- Gentler starting dose: At 7.5 mg, Tolvaptan Zentiva k.s. delivers roughly half the aquaretic response of a 15 mg dose, giving clinicians finer control over the rate of sodium correction – especially valuable in elderly, malnourished, or high-risk patients
- Targeted aquaretic mechanism: Tolvaptan blocks vasopressin V2 receptors in the kidney collecting ducts, causing excretion of free water without loss of sodium or potassium – a mechanism distinct from conventional diuretics
- Hospital initiation is mandatory: The first dose must be given where serum sodium can be checked every 6–8 hours, because correcting chronic hyponatraemia too rapidly can trigger osmotic demyelination syndrome (ODS)
- Fluid restriction is relaxed: Unlike other SIADH treatments, patients must drink freely in response to thirst to prevent dehydration; rigid fluid restriction during the first 24–48 hours is usually not recommended
- Liver function monitoring: Baseline and periodic liver enzyme tests are required because tolvaptan has been associated with rare idiosyncratic liver injury; any jaundice, nausea, or dark urine must be reported immediately
- Avoid grapefruit and strong CYP3A4 inhibitors: Ketoconazole, itraconazole, clarithromycin, and grapefruit juice can increase tolvaptan exposure up to 5-fold, raising the risk of adverse effects including liver toxicity
What Is Tolvaptan Zentiva k.s. and What Is It Used For?
Tolvaptan Zentiva k.s. is a prescription medicine containing 7.5 mg of tolvaptan, a selective vasopressin V2-receptor antagonist. It is used in adults to treat hyponatraemia (low blood sodium) that is caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH), where the body retains too much water relative to sodium. The 7.5 mg strength provides a low-dose starting option particularly useful in patients at risk of rapid sodium correction.
Tolvaptan Zentiva k.s. is a generic form of the original reference product Samsca, developed and marketed by Zentiva, k.s., a Prague-based generics manufacturer with authorisations across European Union and European Economic Area member states. The active substance, tolvaptan, belongs to a class of medicines called vaptans, which act as selective antagonists at the vasopressin V2 receptor. Tolvaptan was the first oral vasopressin antagonist approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of hyponatraemia.
Hyponatraemia is defined as a serum sodium concentration below 135 mmol/L and is the most common electrolyte disturbance encountered in hospitalised patients, affecting up to 30–40% of admissions to medical wards. In SIADH, the pituitary gland or an ectopic source (such as a small-cell lung cancer) secretes antidiuretic hormone (vasopressin) inappropriately, despite the body having a normal or excess water balance. Vasopressin then signals the kidneys to reabsorb water, diluting the blood and producing hyponatraemia. Symptoms range from subtle cognitive slowing, falls, and fatigue in mild cases to confusion, seizures, coma, and death in severe or rapidly developing cases.
Traditional treatments for SIADH include addressing the underlying cause (such as a tumour, infection, or offending medication), fluid restriction of 800–1000 mL per day, oral urea or salt tablets, and, in severe acute hyponatraemia, hypertonic saline. These approaches are often poorly tolerated, slow, or ineffective. Tolvaptan Zentiva k.s. offers a targeted pharmacological solution: by blocking V2 receptors in the renal collecting ducts, it prevents the insertion of aquaporin-2 water channels into the luminal membrane. The result is the excretion of dilute urine – a process called aquaresis – which raises serum sodium without depleting sodium or potassium stores.
The rationale for choosing the 7.5 mg strength rather than the standard 15 mg starting dose is clinical pharmacology. Exposure-response data show that serum sodium rises roughly in proportion to tolvaptan plasma concentrations over the 7.5–60 mg range, and the 7.5 mg dose yields approximately 60% of the peak aquaretic response seen at 15 mg. For patients at elevated risk of over-rapid correction – profoundly hyponatraemic, elderly, cachectic, with liver disease, or with a history of neurological vulnerability – initiating at 7.5 mg improves the safety margin without sacrificing efficacy, because the dose can always be increased after 24–48 hours based on serum sodium response.
Randomised controlled trials, including the pivotal SALT-1 and SALT-2 studies, demonstrated that oral tolvaptan significantly raised serum sodium from day 1 through day 30 of treatment compared to placebo, in both euvolaemic and hypervolaemic hyponatraemia. Subsequent real-world evidence and the SALTWATER extension study confirmed sustained efficacy and safety for longer-term use in selected patients under specialist supervision. Tolvaptan Zentiva k.s. is indicated specifically for euvolaemic hyponatraemia caused by SIADH in the European Union; indications in other regions may also include hypervolaemic hyponatraemia associated with heart failure.
It is important to emphasise that Tolvaptan Zentiva k.s. 7.5 mg is used exclusively for hyponatraemia in SIADH at this strength. A different tolvaptan product (Jinarc/Jynarque, available in 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg tablets) is licensed for autosomal dominant polycystic kidney disease (ADPKD). The two indications must not be confused; dosing schedules, patient selection, and monitoring requirements are entirely different. Tolvaptan Zentiva k.s. is therapeutically equivalent to Samsca 7.5 mg and is substitutable under the prescribing physician’s guidance.
What Should You Know Before Taking Tolvaptan Zentiva k.s.?
Tolvaptan Zentiva k.s. must not be used during pregnancy or breastfeeding, in anuria, in volume-depleted (hypovolaemic) hyponatraemia, in hypernatraemia, or in patients who cannot perceive or respond to thirst. Treatment must begin in hospital because rapid correction of sodium can cause osmotic demyelination syndrome.
Before Tolvaptan Zentiva k.s. is prescribed, your doctor will carefully assess your clinical situation. Hyponatraemia can have many causes – SIADH is only one of them – and the correct diagnosis is essential because tolvaptan is not appropriate for every form of low sodium. Laboratory tests (serum sodium, serum osmolality, urine sodium, urine osmolality, thyroid function, cortisol) and clinical examination of volume status (jugular venous pressure, skin turgor, blood pressure, oedema) are standard before initiation. A careful medication review is also essential, because many commonly prescribed drugs – diuretics, selective serotonin reuptake inhibitors, antiepileptics, certain antipsychotics – can themselves cause or worsen hyponatraemia.
Contraindications
Do not take Tolvaptan Zentiva k.s. if any of the following applies to you:
- You are allergic to tolvaptan or to any of the other ingredients in the tablet
- You are allergic to benzazepine or benzazepine derivatives (for example benazepril, fenoldopam, or conivaptan)
- You have anuria (the kidneys are producing no urine) – there can be no clinical benefit in the absence of urine production
- You have volume depletion that causes your hyponatraemia (hypovolaemic hyponatraemia). In this situation, the correct treatment is to restore intravascular volume, not to induce further water loss
- You have hypernatraemia (serum sodium above the upper limit of normal)
- You cannot perceive or respond to thirst – for example because of coma, severe dementia, or sedation – because tolvaptan dramatically increases urine volume and the ability to drink in response to thirst is essential to prevent dehydration and hypernatraemia
- You are pregnant
- You are breastfeeding
Warnings and Precautions
Speak with your doctor before starting Tolvaptan Zentiva k.s. if any of the following applies. Extra caution or closer monitoring may be required:
- You have current or prior liver disease, or you drink alcohol heavily
- You cannot reliably access water or have difficulty swallowing
- You have urinary outflow obstruction (for example a benign prostatic enlargement or urethral stricture)
- You have diabetes mellitus, because tolvaptan can raise blood glucose
- You have a history of elevated uric acid or gout
- You have advanced chronic kidney disease (efficacy may be reduced if renal function is severely impaired)
- You are elderly or frail – closer monitoring of hydration status and cognitive function is recommended, and the 7.5 mg starting strength is particularly suitable
- You have a cardiac condition with tight blood pressure control
Correcting chronic hyponatraemia too quickly can trigger osmotic demyelination syndrome, a severe and sometimes irreversible neurological disorder affecting myelin in the brainstem and elsewhere. Symptoms include dysarthria, dysphagia, lethargy, altered consciousness, quadriparesis, and seizures, and they often appear 2–6 days after over-rapid sodium correction.
To minimise this risk, Tolvaptan Zentiva k.s. treatment must be initiated in hospital, with serum sodium measured every 6–8 hours during the first 24–48 hours. If sodium rises by more than 10–12 mmol/L in 24 hours or more than 18 mmol/L in 48 hours, tolvaptan should be interrupted and hypotonic fluids (or desmopressin in severe cases) may be administered to slow correction. Patients at highest risk of ODS include those with serum sodium below 120 mmol/L, chronic hyponatraemia of more than 48 hours duration, liver disease, alcohol use disorder, malnutrition, and hypokalaemia – all patient groups where the 7.5 mg starting dose is often preferred.
Potential for Liver Injury
Tolvaptan has been associated with rare but clinically significant idiosyncratic liver injury, most prominently observed in long-term use for ADPKD. In SIADH, where treatment is typically shorter, the absolute risk is lower, but liver function tests (ALT, AST, alkaline phosphatase, bilirubin) should be obtained at baseline and monitored periodically. Most hepatic events are reversible on prompt discontinuation, but failure to stop the drug in time has led to rare cases of acute liver failure requiring transplantation.
Stop taking Tolvaptan Zentiva k.s. and contact your doctor immediately if you develop any of the following, which can indicate liver injury:
- Nausea or vomiting that does not settle
- Unexplained fever or flu-like feeling
- Unusual tiredness, lethargy, or weakness
- Loss of appetite
- Pain or discomfort in the right upper abdomen
- Dark (tea-coloured) urine
- Pale stools
- Yellowing of the skin or the whites of the eyes (jaundice)
- Persistent itching
Dehydration and Rapid Sodium Rise
Because Tolvaptan Zentiva k.s. induces large volumes of dilute urine, dehydration can develop quickly – particularly in older adults, during hot weather, during intercurrent illness with vomiting or diarrhoea, or when fluid intake is inadequate. Signs of dehydration include dry mouth, dizziness when standing, rapid heart rate, decreased urine production, and confusion. Drink to thirst; your medical team will give specific guidance about target daily fluid intake during the first days of treatment. The 7.5 mg strength moderates aquaretic intensity but does not eliminate the need for careful fluid monitoring.
Pregnancy and Breastfeeding
Tolvaptan Zentiva k.s. must not be used during pregnancy. Animal studies have shown teratogenic effects at doses lower than those used therapeutically in humans, and no adequate and well-controlled studies exist in pregnant women. Women of childbearing potential should use effective contraception throughout treatment. If you become pregnant while taking Tolvaptan Zentiva k.s., stop the medication and contact your prescriber without delay.
Breastfeeding is contraindicated during Tolvaptan Zentiva k.s. treatment. Tolvaptan has been detected in the milk of lactating rats, and human data are not available. Given the potential for serious adverse reactions in a nursing infant, a decision must be made either to discontinue breastfeeding or to discontinue the drug, weighing the importance of treatment to the mother.
Children and Adolescents
Tolvaptan Zentiva k.s. is not recommended for children or adolescents under 18 years of age because safety and efficacy in the paediatric population have not been adequately established. Paediatric hyponatraemia is managed using different protocols under specialist supervision, typically involving adjusted fluid prescriptions, hypertonic saline in severe cases, and investigation for underlying causes such as central nervous system infection, hormonal deficiencies, or metabolic disease.
Driving and Using Machines
Tolvaptan Zentiva k.s. can cause dizziness, weakness, and fatigue, especially at the start of treatment or after dose changes. Do not drive a vehicle, operate heavy machinery, or perform other tasks requiring alertness until you know how the medicine affects you. The large volumes of urine produced may also cause practical difficulty on long journeys without access to a toilet; patients should plan activities accordingly during the first days of therapy.
Lactose Content
Tolvaptan Zentiva k.s. 7.5 mg tablets contain lactose monohydrate as an excipient. If you have been told by your doctor that you have an intolerance to certain sugars, speak with your doctor before taking this medicine. Patients with the rare hereditary conditions galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
How Does Tolvaptan Zentiva k.s. Interact with Other Drugs?
Tolvaptan Zentiva k.s. is extensively metabolised by CYP3A4 and is a substrate and inhibitor of P-glycoprotein. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) are contraindicated. CYP3A4 inducers (rifampicin, carbamazepine, St John’s wort) can reduce efficacy. Avoid grapefruit juice. Tell your doctor about every medicine you take.
Drug interactions are an important consideration with Tolvaptan Zentiva k.s. because tolvaptan has a relatively narrow therapeutic window in terms of sodium response, and altered plasma concentrations can either reduce efficacy or increase the risk of side effects, including liver injury. Always inform every prescriber, pharmacist, and nurse involved in your care that you are taking Tolvaptan Zentiva k.s., and bring an up-to-date medication list to every appointment. The 7.5 mg starting strength provides some pharmacokinetic “headroom” against moderate CYP3A4 inhibition, but this advantage must not be relied on to justify co-administration with strong inhibitors.
Major Interactions – Drugs That Increase the Effect of Tolvaptan Zentiva k.s.
CYP3A4 inhibitors slow the metabolism of tolvaptan and raise its blood concentration. The interaction can be clinically important because higher tolvaptan concentrations translate into greater aquaretic effect (risking over-rapid sodium correction and dehydration) and potentially greater hepatotoxic risk. Even at the 7.5 mg starting dose, co-administration with a strong CYP3A4 inhibitor can raise effective exposure to levels equivalent to 30 mg or more of unaffected tolvaptan.
| Drug | Therapeutic Use | Interaction Mechanism | Clinical Advice |
|---|---|---|---|
| Ketoconazole | Systemic antifungal | Strong CYP3A4 inhibitor; increases tolvaptan exposure (AUC) up to 5-fold | Contraindicated. Do not combine. |
| Itraconazole, Voriconazole | Systemic antifungal agents | Strong CYP3A4 inhibition | Avoid. If unavoidable, keep dose at 7.5 mg and monitor very closely. |
| Clarithromycin, Telithromycin | Macrolide antibiotics | Strong CYP3A4 inhibition | Avoid during tolvaptan treatment. Consider azithromycin as alternative. |
| Ritonavir, Cobicistat, Indinavir, Nelfinavir | HIV protease inhibitors and boosters | Very strong CYP3A4 inhibition | Avoid combination. Specialist review required if essential. |
| Erythromycin, Diltiazem, Verapamil | Antibiotic / cardiovascular | Moderate CYP3A4 inhibition | Maintain at 7.5 mg and monitor serum sodium closely; avoid dose escalation without specialist review. |
| Fluconazole, Aprepitant | Antifungal / antiemetic | Moderate CYP3A4 inhibition | Consider maintaining low dose. Monitor sodium and liver enzymes. |
| Amiodarone | Antiarrhythmic | Weak to moderate CYP3A4 inhibition; long half-life | Use with caution. Monitor closely. |
| Grapefruit juice and whole grapefruit | Dietary | Inhibits intestinal CYP3A4 | Avoid entirely while on Tolvaptan Zentiva k.s. |
Minor Interactions – Drugs That Decrease the Effect of Tolvaptan Zentiva k.s.
CYP3A4 inducers accelerate the metabolism of tolvaptan and may reduce plasma concentrations to subtherapeutic levels, meaning the medicine may not correct the serum sodium as expected. Because 7.5 mg is already a low dose, the impact of induction can be proportionally larger than at higher strengths, and co-prescription should be approached carefully.
| Drug | Therapeutic Use | Clinical Advice |
|---|---|---|
| Rifampicin, Rifabutin, Rifapentin | Tuberculosis and atypical mycobacterial infection | Can substantially reduce tolvaptan exposure. Avoid combination when possible; alternative management of hyponatraemia should be considered. |
| Phenytoin, Carbamazepine, Phenobarbital | Epilepsy | Consider alternative antiepileptics under neurology supervision. Monitor sodium carefully if unavoidable. |
| Efavirenz, Etravirine, Nevirapine | HIV non-nucleoside reverse transcriptase inhibitors | Can reduce tolvaptan levels. Consult HIV specialist. |
| St John’s wort (Hypericum perforatum) | Herbal remedy for mild depression | Avoid during tolvaptan treatment. |
Drugs Whose Effect May Be Increased by Tolvaptan Zentiva k.s.
Tolvaptan inhibits the P-glycoprotein (P-gp) efflux transporter and organic anion transporting polypeptide (OATP). This can raise blood levels of certain drugs that are transported by these systems.
- Digoxin (used for atrial fibrillation and heart failure) – plasma levels can rise. Monitor digoxin concentration and adjust the dose as needed.
- Dabigatran (oral anticoagulant) – exposure can increase, raising the risk of bleeding. Consider an alternative anticoagulant or monitor for bleeding.
- Sulfasalazine (used in inflammatory bowel disease and rheumatoid arthritis) – levels may be elevated.
- Methotrexate – plasma concentrations may increase. Monitor for toxicity, particularly in high-dose oncology regimens.
- Statins (for example atorvastatin, simvastatin) – potential mild increase in exposure. Be alert for muscle pain or weakness.
Drugs Whose Effect May Be Decreased by Tolvaptan Zentiva k.s.
- Desmopressin (DDAVP) and other vasopressin analogues – used for diabetes insipidus, nocturnal enuresis, haemophilia A, or von Willebrand disease. Tolvaptan directly antagonises their V2-receptor action, reducing their effectiveness. The one clinical exception is deliberate use of desmopressin to reverse over-rapid sodium correction from tolvaptan, under specialist supervision.
Other Important Interactions
- Loop and thiazide diuretics (for example furosemide, hydrochlorothiazide) – when combined with Tolvaptan Zentiva k.s., the risk of dehydration and electrolyte imbalance is increased. Careful titration and frequent electrolyte monitoring are essential.
- Hypertonic saline (3% NaCl) – rarely indicated together with tolvaptan; if used, the risk of over-rapid sodium correction is substantial and specialist supervision is mandatory.
- Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) – combined with tolvaptan, hypotension may be more pronounced. Rise from sitting or lying slowly.
- Warfarin and other vitamin K antagonists – tolvaptan can alter anticoagulant effect indirectly through changes in fluid balance. Monitor INR more frequently during the first week of tolvaptan therapy.
- Potassium-containing salts or potassium-sparing diuretics – although tolvaptan does not directly affect potassium, changes in plasma volume can influence potassium concentration. Monitor electrolytes as a panel.
- Effervescent medicines and oral sodium chloride supplements – contain large amounts of sodium. Use under medical advice only while on tolvaptan.
What Is the Correct Dosage of Tolvaptan Zentiva k.s.?
The recommended starting dose of Tolvaptan Zentiva k.s. is 7.5 mg once daily, taken orally with or without food. This low-dose start allows gradual sodium correction and is particularly suitable for elderly, frail, or high-risk patients. The dose may be increased after at least 24 hours, typically to 15 mg and then in stepwise increments up to a maximum of 60 mg once daily, based on serum sodium response and tolerability. Treatment must be initiated in hospital with frequent serum sodium measurements.
Tolvaptan Zentiva k.s. should only be prescribed by physicians experienced in the management of hyponatraemia and initiated in a setting where laboratory results can be turned around rapidly. The goal of therapy is to increase serum sodium gradually, typically aiming for a rise of no more than 10–12 mmol/L in the first 24 hours and no more than 18 mmol/L over 48 hours. Treatment length depends on the underlying cause of SIADH – days for reversible causes such as an infection or an offending medication, weeks to months for chronic SIADH due to a non-resectable tumour or chronic illness. The availability of the 7.5 mg strength means that gradual up-titration is possible without large incremental jumps in aquaretic effect.
Adults – Starting and Titration
Take Tolvaptan Zentiva k.s. 7.5 mg once daily in the morning. The tablet should be swallowed whole with a glass of water and may be taken with or without food. Avoid grapefruit juice entirely.
Tolvaptan Zentiva k.s. Titration Schedule for SIADH Hyponatraemia
| Day | Oral Dose | Titration Decision | Monitoring |
|---|---|---|---|
| Day 1 (starting dose) | 7.5 mg once daily | Do not titrate on day 1 regardless of response | Serum sodium at 6 h, 12 h, and 24 h after first dose |
| Day 2 | 7.5 mg or increase to 15 mg | Increase only if sodium has risen less than 5 mmol/L in 24 h and remains below 135 mmol/L | Serum sodium every 8–12 h; daily fluid balance, weight, blood pressure |
| Day 3 | 15 mg or increase to 30 mg | Increase cautiously based on sodium trajectory and tolerability | Serum sodium every 12 h; daily weight and fluid balance |
| Day 4 onward | 30 mg or increase to 60 mg (maximum) | Uptitrate only if response is clearly insufficient; do not exceed 60 mg/day | Daily serum sodium once stabilised; weekly thereafter in outpatients |
| Maintenance | Lowest effective dose (7.5–60 mg) | Down-titrate if sodium >145 mmol/L or if aquaretic effect too vigorous; many patients are maintained on 7.5 or 15 mg | Monthly sodium, liver enzymes, and renal function in long-term therapy |
If serum sodium rises by more than 12 mmol/L in 24 hours, Tolvaptan Zentiva k.s. should be withheld and sodium correction slowed by giving additional water (oral or intravenous 5% dextrose). In severe over-correction, desmopressin may be considered under specialist supervision. A substantial minority of patients respond adequately to 7.5–15 mg daily, particularly those with moderate SIADH or reduced lean body mass.
Fluid Intake During Treatment
Unlike conventional management of SIADH, strict fluid restriction is not recommended during the first 24–48 hours of Tolvaptan Zentiva k.s. therapy because combining fluid restriction with the aquaretic effect can cause the sodium to rise dangerously quickly. Patients should drink to thirst. Once sodium is stabilised, a moderate fluid intake of approximately 1.5–2 litres per day is usual, adjusted by the treating team based on body weight, urine output, and any co-existing heart failure or kidney disease.
Children and Adolescents
Tolvaptan Zentiva k.s. is not licensed in children and adolescents below 18 years of age. Paediatric hyponatraemia management follows different protocols centred on fluid management and treatment of the underlying cause.
Elderly Patients
No specific dose reduction is required for elderly patients, but older adults are more vulnerable to dehydration, falls, and cognitive disturbances related to rapid sodium shifts. The 7.5 mg strength is especially well suited to elderly initiation, giving clinicians the option of a gentle response before considering up-titration. Frequent clinical review, attention to fall risk, and slow titration are recommended.
Patients with Renal Impairment
Tolvaptan Zentiva k.s. has no meaningful benefit in patients with anuria and is contraindicated in that setting. In severe chronic kidney disease (eGFR below 10 mL/min/1.73 m²), efficacy is reduced, and the benefit-risk balance should be reassessed. No specific dose adjustment is recommended in mild to moderate renal impairment, although the 7.5 mg dose is often appropriate in this subgroup.
Patients with Hepatic Impairment
Given the rare but documented risk of hepatotoxicity, Tolvaptan Zentiva k.s. should be used with caution in patients with underlying liver disease, and the 7.5 mg starting dose is strongly preferred in this context. Baseline liver function tests are mandatory, and periodic monitoring is recommended during treatment. Treatment should be discontinued if significant ALT elevation (>3× upper limit of normal) occurs in combination with bilirubin elevation (>2× upper limit of normal) without an alternative explanation.
Missed Dose
If you forget to take your dose of Tolvaptan Zentiva k.s., take it as soon as you remember on the same day. If it is almost time for the next scheduled dose, skip the missed dose. Never take a double dose to make up for a missed one. Inform your healthcare team if missed doses are frequent, because they can affect the ongoing sodium trajectory.
Overdose
If more tablets have been taken than prescribed, drink plenty of water and seek urgent medical attention. Bring the tablet packaging so the medical team can see exactly what has been taken. Overdose may cause excessive urine output, severe dehydration, hypernatraemia, and electrolyte disturbance; hospital management with intravenous fluids and careful sodium monitoring is required. Tolvaptan is highly protein-bound and therefore not significantly removed by haemodialysis.
Stopping Tolvaptan Zentiva k.s. suddenly can allow serum sodium to fall rapidly, particularly if the underlying cause of SIADH remains uncontrolled. Any decision to stop treatment should be made with the prescribing physician, who will usually monitor sodium during and after discontinuation.
What Are the Side Effects of Tolvaptan Zentiva k.s.?
The most common side effects of Tolvaptan Zentiva k.s. are thirst, dry mouth, frequent urination, nausea, and postural dizziness – all largely related to its aquaretic mechanism. At 7.5 mg, many of these effects are less intense than at higher doses. Rare but serious risks include over-rapid correction of sodium (osmotic demyelination syndrome), idiosyncratic liver injury, and severe dehydration.
Like every medicine, Tolvaptan Zentiva k.s. can produce side effects, although not everyone experiences them. Because tolvaptan’s therapeutic effect is to increase water excretion, many of the frequently reported effects are predictable consequences of its mechanism rather than true toxicity, and they are typically milder at the 7.5 mg dose than at higher strengths. The categories below follow the standard Council for International Organizations of Medical Sciences (CIOMS) frequency classification used in European product information.
Very Common Side Effects
- Intense thirst
- Dry mouth
- Increased urine output (polyuria)
- Increased urinary frequency (pollakiuria)
- Nausea
Common Side Effects
- Dehydration
- Hypernatraemia (high blood sodium)
- Hyperkalaemia (high potassium)
- Hyperglycaemia (high blood sugar)
- Hyperuricaemia and gout flares
- Decreased appetite
- Headache
- Dizziness and postural (orthostatic) hypotension
- Syncope (fainting)
- Fatigue and general weakness (asthenia)
- Dry skin and rash
- Pruritus (itching)
- Constipation
- Nocturia (waking at night to urinate)
- Increased hepatic enzymes (ALT, AST) on blood tests
- Pyrexia (fever)
- Thirst-related sleep disturbance
Uncommon Side Effects
- Dysgeusia (altered taste)
- Palpitations
- Raised creatinine and urea
- Disseminated intravascular coagulation
- Diabetic ketoacidosis in patients with diabetes
- Worsening kidney function in those with pre-existing renal impairment
- Elevated bilirubin
- Urticaria (hives)
- Pruritic rash
- Muscle cramps
- Vaginal haemorrhage
- Raised creatine phosphokinase (CK)
Rare Side Effects
- Osmotic demyelination syndrome (central pontine or extrapontine myelinolysis) following over-rapid sodium correction
- Acute hepatocellular injury progressing to liver failure
- Anaphylactic reactions with facial swelling and bronchospasm
- Severe rash with systemic symptoms
- Ischaemic colitis in volume-depleted older patients
Not Known Frequency
- Acute liver failure requiring transplantation (reported in post-marketing surveillance, predominantly in ADPKD long-term use)
- Severe generalised allergic reaction with angio-oedema
- Stevens–Johnson syndrome (extremely rare)
- Profound muscle weakness and myopathy
- Difficulty swallowing, slurred speech, or severe muscle weakness developing 2–6 days after starting treatment (possible osmotic demyelination)
- Yellowing of the skin or eyes, dark urine, right upper abdominal pain, or profound fatigue (possible liver injury)
- Facial, lip, or tongue swelling, widespread rash, or sudden wheezing (possible anaphylaxis)
- Fainting, severe dizziness, very rapid heart rate, or confusion (possible severe dehydration or hypotension)
Stop taking Tolvaptan Zentiva k.s. and go to the nearest emergency department.
Reporting Side Effects
Post-marketing pharmacovigilance depends on patients and healthcare professionals reporting adverse reactions. Report any suspected side effect to your national regulatory authority, such as the EMA national competent authority in the EU, the FDA MedWatch programme in the United States, the MHRA Yellow Card Scheme in the United Kingdom, or Health Canada’s MedEffect portal. Reporting helps ensure continuing surveillance of the safety of Tolvaptan Zentiva k.s.
How Should You Store Tolvaptan Zentiva k.s.?
Store Tolvaptan Zentiva k.s. tablets in the original blister pack at room temperature (below 30°C), protected from light and moisture. Keep out of the reach and sight of children. Do not use after the expiry date printed on the carton. Return unused tablets to a pharmacy for safe disposal.
Correct storage protects the quality and safety of Tolvaptan Zentiva k.s. throughout its shelf life. Follow the guidance below and the instructions supplied in the carton:
- Store below 30°C – avoid direct sunlight, hot cars, and humid bathrooms
- Keep in the original packaging (blister and carton) until use to protect from light and moisture
- Do not refrigerate or freeze – the tablets are stable at room temperature and do not require cold storage
- Keep out of reach and sight of children – even a single 7.5 mg tablet could cause significant adverse effects in a young child
- Check the expiry date printed on the carton and blister; the date refers to the last day of the stated month
- Inspect the tablets before use; do not use tablets that look damaged, discoloured, crumbly, or damp
- Disposal – do not throw unused or expired Tolvaptan Zentiva k.s. down the sink, toilet, or household rubbish. Return unused tablets to a pharmacy for environmentally safe disposal. These measures help protect water systems
What Does Tolvaptan Zentiva k.s. Contain?
Each film-coated tablet contains 7.5 mg of tolvaptan as the active substance. Excipients include lactose monohydrate, microcrystalline cellulose, magnesium stearate, maize starch, hydroxypropyl cellulose, and a blue pigment from indigo carmine aluminium lake.
Active Ingredient
The active ingredient is tolvaptan. Each tablet contains 7.5 mg of tolvaptan.
Other Ingredients (Excipients)
The tablet core contains: lactose monohydrate, microcrystalline cellulose, maize starch, hydroxypropyl cellulose, and magnesium stearate. The tablet coating contains hypromellose, titanium dioxide (E171), macrogol, talc, and indigo carmine aluminium lake (E132). Exact excipient composition may vary slightly between production batches and national market authorisations but remains equivalent to the reference product Samsca for bioequivalence purposes.
Tablet Appearance
Tolvaptan Zentiva k.s. 7.5 mg tablets are pale blue film-coated tablets, debossed with an identification code on one face. The tablet geometry and identifying marks are harmonised with the reference product Samsca to aid recognition by patients, carers, and healthcare staff, and to differentiate the hyponatraemia strength from higher-strength tolvaptan tablets used for ADPKD.
Pack Sizes
Tolvaptan Zentiva k.s. 7.5 mg is typically supplied in blister packs of 10 tablets or 30 tablets, packaged within an outer carton together with the patient information leaflet. Not all pack sizes are marketed in every country. Your pharmacist can dispense the smallest pack that meets your prescription when shorter courses are prescribed.
Manufacturer and Marketing Authorisation Holder
Tolvaptan Zentiva k.s. is marketed by Zentiva, k.s., U kabelovny 130, 102 37 Prague 10, Czech Republic. Zentiva is one of Europe’s leading generic pharmaceutical manufacturers, with regulatory authorisations across the European Union and European Economic Area. The product has been authorised through national or decentralised procedures as a generic of Samsca (reference product originally developed by Otsuka Pharmaceutical). The summary of product characteristics (SmPC) specific to each national authorisation can be obtained from the relevant regulatory authority.
Frequently Asked Questions About Tolvaptan Zentiva k.s.
Medical References and Sources
- European Medicines Agency (EMA). Samsca (tolvaptan) – Summary of Product Characteristics (SmPC). EPAR last updated 2024. Available at: ema.europa.eu/en/medicines/human/EPAR/samsca
- Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–2112. doi:10.1056/NEJMoa065181 (SALT-1 and SALT-2 trials)
- Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21(4):705–712. doi:10.1681/ASN.2009080857 (SALTWATER extension)
- Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170(3):G1–G47. doi:10.1530/EJE-13-1020 (European Society of Endocrinology Guideline, endorsed by ESICM and ERA-EDTA)
- Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1–S42. doi:10.1016/j.amjmed.2013.07.006
- U.S. Food and Drug Administration (FDA). Samsca (tolvaptan) – Prescribing Information. Available at: accessdata.fda.gov
- Hoorn EJ, Zietse R. Diagnosis and treatment of hyponatremia: compilation of the guidelines. J Am Soc Nephrol. 2017;28(5):1340–1349. doi:10.1681/ASN.2016101139
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: World Health Organization; 2023.
- Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab. 2003;17(4):471–503. doi:10.1016/S1521-690X(03)00049-6
- Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–2418. doi:10.1056/NEJMoa1205511 (comparative context for ADPKD use)
- British National Formulary (BNF). Tolvaptan – indications, cautions, and monitoring. London: BMJ Group and Pharmaceutical Press; 2025.
- Sterns RH. Disorders of plasma sodium – causes, consequences, and correction. N Engl J Med. 2015;372(1):55–65. doi:10.1056/NEJMra1404489
- Grattagliano I, Bonfrate L, Ruggiero V, et al. Management of hyponatraemia in the elderly: role of aquaretics. Drugs Aging. 2018;35(8):673–684. doi:10.1007/s40266-018-0562-2
Editorial Team
This article has been written and medically reviewed by our specialist editorial team, following international clinical guidelines and evidence-based standards.
Medical Content Team
Board-certified physicians with clinical expertise in fluid and electrolyte disorders, SIADH, endocrine emergencies, and the pharmacology of vasopressin antagonists.
Medical Review Board
Content undergoes rigorous review by an independent panel of medical experts following the GRADE evidence framework and the guidelines of the European Society of Endocrinology, EMA, and FDA.
Editorial Standards
Evidence Level 1A. No commercial funding or pharmaceutical company sponsorship. Independent medical editorial content reviewed according to international standards.